Claes Buxfeldt, former Global Price and Reimbursement Director at AstraZeneca, has joined the NDA Advisory Board. Claes brings with him a wealth of knowledge and experience from his time in industry. For clients of the leading drug development consultancy this means faster provision of market access enabling advice and support.
During the last 18 years Claes has worked on a variety of disease areas, supporting more than 30 molecules/brands in a global position. He has represented the payer voice in the development programs including the development of payer evidence strategies, pricing and market access strategy, economic models, PROs, RWE and clinical program input.
He joined AstraZeneca in 2009 as Value Demonstration Leader in Global Health Economics & Outcomes Research, moving onto becoming the Global Price & Reimbursement Director in Respiratory & Inflammation.
Claes is joining the NDA Advisory Board as HTA director, where he aims to drive and develop NDA’s leading service offerings in the HTA area.
The NDA Advisory Board is a unique team of experts comprising of some of the most well-known names in the industry, many of whom have been involved in designing the regulatory and HTA systems in place today. Together, they provide strategic advice and unbiased second opinions to pharmaceutical clients during part of, or the complete end-to-end drug development life cycle. This also includes support and advice during interaction with regulatory agencies, be it at scientific advice, during review of a marketing authorisation application or at any stage post-authorisation.
Dr Werner Van den Eynde, Vice President NDA Advisory Board, commented on the appointment:
“We are very happy to welcome Claes on board as our new HTA Director. The impact of HTA and market access on the pharma industry is growing every day. Claes’ expertise and long experience in these areas will allow us to provide an even better service to our clients.”